Olaratumab is a platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS). Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding.
- Mechanism
- Curator reviewed · 1 reference
Olaratumab blocks ligand-induced tumor cell proliferation, and inhibits receptor autophosphorylation and ligand-induced phosphorylation of the downstream signaling molecules protein kinase B (Akt) and mitogen-activated protein kinase. PDGFR signalling is a type of tyrosine kinase-mediated pathway that normally regulates cell growth, chemotaxis, and mesenchymal stem cell differentiation. It also promotes internalization of PDGFR thus alters the surface levels of PDGFR.
- Primary indication
- Olaratumab is indicated, in combination with doxorubicin, for the treatment of adult patients with advanced or mestastatic soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is...Curator reviewed · 1 structured indication
- Formula / weight
- C6554H10076N1736O2048S40 · 154000.0 Da (147200 Da without glycan mass/154600 Da with glycan mass)
- First approval
- Canada, 2017 · United States, 2016
- Code names
- IMC-3G3
- Brand names
Resolves to
What you can answer from here — as of September 17, 2026
Which drugs share a target with Olaratumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account